Surgical Science Sweden ABSUSRF -2.20%82 Altman Z-Score is 3.08 as of Jun. 26, 2026, which is 77% below its 10-year median of 13.43. GuruFocus rates SUSRF with a GF Score™ of 82/100 and a GF Value™ of $14.30 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 662 Healthcare Providers & Services companies, Surgical Science Sweden AB ranks better than 61.18% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 3.12 is strong.
Surgical Science Sweden AB has a Altman Z-Score of 3.08, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Surgical Science Sweden AB's Altman Z-Score or its related term are showing as below:
SUSRF'
s Altman Z-Score Range Over the Past 10 Years
Min: 0.37 Med: 13.43 Max: 43.41
Current: 3.12
During the past 11 years, Surgical Science Sweden AB's highest Altman Z-Score was 43.41. The lowest was 0.37. And the median was 13.43.
Surgical Science Sweden AB (OTCPK:SUSRF) Altman Z-Score Explanation
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SUSRF vs VEEV, BTSG, TEM: Altman Z-Score Comparison
For the Health Information Services subindustry, Surgical Science Sweden AB's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Surgical Science Sweden AB Altman Z-Score vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Surgical Science Sweden AB's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Surgical Science Sweden AB's Altman Z-Score falls into.
Surgical Science Sweden AB Altman Z-Score Calculation
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Surgical Science Sweden AB (SUSRF) has a Altman Z-Score of 3.08 as of Jun. 26, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Surgical Science Sweden AB and its competitors. This is 77% below median its historical median of 13.43. Over the past decade, Surgical Science Sweden AB's Altman Z-Score has ranged from 0.37 to 43.41. According to the industry distribution chart, Surgical Science Sweden AB ranks #257 out of 662 companies in the Healthcare Providers & Services industry, placing it in the top 38.8%.
Is Surgical Science Sweden AB's Altman Z-Score too high?
Surgical Science Sweden AB's current Altman Z-Score of 3.08 is 77% below median its 10-year median of 13.43. Over the past 10 years, this metric has ranged from a low of 0.37 to a high of 43.41. The Healthcare Providers & Services industry median Altman Z-Score is 2.36. Surgical Science Sweden AB's value of 3.08 is 30.5% above this industry median. Based on the distribution chart, Surgical Science Sweden AB ranks #257 out of 662 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Surgical Science Sweden AB has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Surgical Science Sweden AB's Altman Z-Score compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Surgical Science Sweden AB ranks #257 out of 662 companies for Altman Z-Score. This puts Surgical Science Sweden AB in the upper half of its industry. The industry median Altman Z-Score is 2.36. Surgical Science Sweden AB's value of 3.08 is 30.5% above this benchmark. Historically, Surgical Science Sweden AB's own Altman Z-Score has ranged from 0.37 to 43.41 over the past decade. While the company's 10-year median is 13.43 vs. the industry median of 2.36, Surgical Science Sweden AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Healthcare Providers & Services company?
The median Altman Z-Score among Healthcare Providers & Services companies is 2.36, based on 662 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Surgical Science Sweden AB's current Altman Z-Score of 3.08 is 30.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Surgical Science Sweden AB and its competitors. For the Healthcare Providers & Services industry, the median Altman Z-Score is 2.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Surgical Science Sweden AB's current Altman Z-Score is 3.08, which is 77% below median its own 10-year median of 13.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Surgical Science Sweden AB stock overvalued right now?
Based on GuruFocus' analysis, Surgical Science Sweden AB (SUSRF) is currently considered Significantly Undervalued. The stock's GF Value™ is $14.30, compared to a current price of $4.00 — trading 72% below its estimated fair value. The current Altman Z-Score is 3.08, which is 77% below median its 10-year median of 13.43 and 30.5% above the Healthcare Providers & Services industry median of 2.36. Surgical Science Sweden AB's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Surgical Science Sweden AB (SUSRF), the current Altman Z-Score is 3.08 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Surgical Science Sweden AB (SUSRF) Overvalued in 2026?
Based on GuruFocus' analysis, Surgical Science Sweden AB stock appears to be undervalued.
The current stock price of $4.00 is trading 72% below its estimated GF Value™ of $14.30.
GuruFocus considers Surgical Science Sweden AB to be Significantly Undervalued.
Key valuation signals for SUSRF:
Altman Z-Score: 3.08 (77% below median its 10-year median of 13.43)
GF Value™: $14.30 vs. price of $4.00 (72% below fair value)
Industry Position: 30.5% above the Healthcare Providers & Services median (#257 of 662)
No single metric tells the full story. See the SUSRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Surgical Science Sweden AB is a supplier of virtual reality simulators for medical training. The company's core is its proprietary software and hardware for simulating interactions between instruments and anatomy. It has two operating segments: Educational products include Proprietary brand medical simulator hardware and software for generic training of psycho-motor skills, instrument handling, and training for a large number of procedures and examinations prior to entering the clinical environment, as well as support and services. Industry/OEM includes simulation software for product-specific training of surgeons in robot-assisted surgery and other digitalized medical instruments, and also simulators for medical device companies.
82GF Score
Get the complete analysis for SUSRF
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SUSRF has been successfully added to your 
